Scancell Holdings

SCLP: 6.30 0.00 (0.00%) delayed: 18 Feb 2020, 16:57

Trade now

Scancell Holdings Fundamentals

Share Price Information

Name Scancell Holdings
Epic SCLP
Sector Biotechnology
ISIN GB00B63D3314
Activites Scancell Holdings plc is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms. Scancell's first ImmunoBody, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence. Scancell's ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site, and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells. Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that have the ability to destroy tumours with minimal toxicity. The Directors believe that the Moditope platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
Index n/a

Key numbers

Latest Share price (p) 0.00 Net gearing (%) -31.82
Market capitalisation (£m) 33.27 Gross gearing (%) 11.43
Shares in issue (m) 465.36 Debt ratio 0.00
P/E ratio -4.93 Debt-to-equity ratio 0.00
Total dividends per share (p) 0.00 Assets / equity ratio 1.13
Dividend yield (%) 0.00 Price to book value 3.56
Dividend cover 0.00 ROCE (%) -71.92
Earning per share (p) -1.45 EPS growth (%) -8.21
52-week high / low (p) 9.75 / 3.70 DPS growth (%) n/a

Results at a glance

Date Type Turnover (£m) Profit (£m) Basic EPS Currency
30 Apr 2019 Full Year 0 -6 -1.45 GBP
30 Apr 2018 Full Year 0 -4 -1.34 GBP
30 Apr 2017 Full Year 0 -4 -1.36 GBP

Dividend history

Period Ex-date Pay-date Net dividend Currency Total for year

Contact details

Company name Scancell Holdings
Address City Hospital, Hucknall Road, Nottingham NG5 1PB.
Telephone +44 (0)115 823 1863
Website http://www.scancell.co.uk/

Advisors

Company's broker Cenkos Securities Limited
Company's joint broker n/a
NOMAD Cenkos Securities Limited
Registrar SLC Registrars Ltd
Auditors Champion Accountants
Solicitors Laytons

Directors

Appointed Director Position
10 Jan 2018 Dr Clifford Michael Holloway Chief Executive Officer
15 Apr 2008 Prof Linda Gillian Durrant Chief Scientific Officer
15 Apr 2008 Dr Richard Morley Goodfellow Executive Director
01 May 2014 Dr Sally Elizabeth Adams Executive Director
14 Oct 2015 Dr John Chiplin Non-Executive Chairman
22 Aug 2016 Dr Alan James Lewis Non-Executive Director
18 Jun 2019 Martin Henry Diggle Non-Executive Director
23 Oct 2019 Dr Ursula Mary Ney Non-Executive Director

Company financials

Assets (£m) 2019 2018 2017
Reporting date 30 Apr 2019 30 Apr 2018 30 Apr 2017
Tangible assets 0 0 0
Intangible asssets and goodwill 3 3 3
Investments and other non-current assets 0 0 0
Total non-current assets 3 3 4
Inventory / work in progress 0 0 0
Trade and other receivables 1 0 0
Cash and equivalents 5 10 3
Other current assets and asset held for resale 2 1 1
Total of all assets 11 15 7
Liabilities (£m) 2019 2018 2017
Short term liabilities 1 1 1
Long term liabilities 0 0 0
Other liabilites / pension etc 0 0 0
Total of all liabilities 1 1 1
Net assets (£m) 2019 2018 2017
Net assets 9 14 7
Equity (£m) 2019 2018 2017
Share capital 0 0 0
Minority interests 0 0 0
Retained earnings -26 -20 -16
Share premium account 35 33 22
Other equity 0 1 1
Total equity 9 14 7
Cash Flow (£m) 2019 2018 2017
Cash from operating activities -7 -4 -4
Cashflow before financing -7 -4 -4
Increase / decrease in Cash -6 8 -4
Income (£m) 2019 2018 2017
Turnover 0 0 0
Cost of sales 0 0 0
Gross profit 0 0 0
Operating profit -7 -5 -5
Pre-tax profit -7 -5 -5
Profit / loss for the year -6 -4 -4